Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (HBIO) delivers specialized scientific instruments that power breakthroughs in life sciences research and drug discovery. This dedicated news hub provides investors and researchers with essential updates on corporate developments shaping the preclinical research sector.
Access authoritative coverage of HBIO's financial announcements, product innovations, and strategic initiatives. Our curated collection includes earnings reports, regulatory filings, technology launches, and partnership updates – all critical for assessing the company's role in advancing laboratory science worldwide.
Key updates span electrophysiology platform enhancements, telemetry system deployments, and organoid research advancements. Track how HBIO's global distribution network supports pharmaceutical developers and academic institutions through reliable instrumentation solutions.
Bookmark this page for streamlined monitoring of Harvard Bioscience's operational milestones. Verify research trends and corporate health through primary-source updates from the company's investor relations communications and verified media coverage.
Harvard Bioscience reported Q1 2023 revenues of $30 million, a 4% increase from Q1 2022. The company achieved a GAAP operating income of $1.7 million, compared to a loss of $6.7 million in the previous year. Adjusted operating income rose to $4.4 million, up from $2.4 million in Q1 '22. The gross margin improved to 61% from 56% year-over-year. Net income was $0.6 million, a notable recovery from a net loss of $6.9 million. Adjusted EBITDA increased to $4.8 million, reflecting a margin of 16% compared to 9% last year. The company expects mid-single-digit revenue growth for 2023, factoring in challenges from discontinued products.
Harvard Bioscience (Nasdaq: HBIO) announced an initial order for its new high-capacity behavioral monitoring system aimed at pre-clinical applications. This order, from a large contract research organization (CRO), is set for delivery in Q4 2023. The company anticipates broader product launches in the second half of 2023, integrating its Panlab® technology with Ponemah™ pre-clinical data management software in a GLP-compliant solution.
Serge Savard, VP of Product Management, emphasized the high throughput and accuracy of the system for neuroscience assessments and drug screening. CEO Jim Green noted that this order reflects the company's commitment to advancing academic research while expanding their product line for larger customers. This development is positioned to enhance Harvard Bioscience's service offerings and market presence.
Harvard Bioscience (Nasdaq: HBIO) is set to announce its financial results for Q1 2023 on April 25, 2023, before market opening. A conference call is scheduled for 9:00 a.m. Eastern Time, allowing participants to register for questions. The financial details and accompanying slide presentation will be available in the Investor Relations section of their website. Harvard Bioscience specializes in technologies and services for life sciences applications across research and pharmaceutical development, catering to a diverse clientele from academic institutions to contract research organizations globally.
Harvard Bioscience (Nasdaq: HBIO) announced that CEO Jim Green will present at the Sidoti Virtual Investor Conference on March 22-23, 2023. He is scheduled to present on March 22 at 10:00 AM ET, and a live webcast will be accessible through their website. The presentation will also be archived for a limited time. Additionally, the company will facilitate one-on-one meetings with investors on both days.
FAQ
What is the current stock price of Harvard Biosci (HBIO)?
What is the market cap of Harvard Biosci (HBIO)?
